{"id":"tak-881","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Hypotension"},{"rate":"null","effect":"Increased urination"}]},"_chembl":{"chemblId":"CHEMBL6010909","moleculeType":null,"molecularWeight":"558.78"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, TAK-881 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes, as it helps to improve glycemic control and reduce the risk of cardiovascular events.","oneSentence":"TAK-881 is a selective, potent, and orally bioavailable inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:19.068Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"},{"name":"Chronic kidney disease"}]},"trialDetails":[{"nctId":"NCT05755035","phase":"PHASE2, PHASE3","title":"A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-10-24","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":65},{"nctId":"NCT06747351","phase":"PHASE3","title":"A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-05-06","conditions":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","enrollment":59},{"nctId":"NCT06935266","phase":"PHASE1","title":"A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2025-04-22","conditions":"Healthy Volunteers","enrollment":64},{"nctId":"NCT06895967","phase":"PHASE1","title":"A Study of TAK-881 and HyQvia in Healthy Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2025-03-24","conditions":"Healthy Volunteers","enrollment":30},{"nctId":"NCT06076642","phase":"PHASE3","title":"A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-11-04","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":39},{"nctId":"NCT06955793","phase":"","title":"Expanded Access to TAK-881 for Children and Teenagers With Primary Immunodeficiency Diseases in the USA","status":"AVAILABLE","sponsor":"Takeda","startDate":"","conditions":"Primary Immunodeficiency Diseases (PIDD)","enrollment":""},{"nctId":"NCT05059977","phase":"PHASE1","title":"A Study of TAK-881 in Healthy Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-10-12","conditions":"Healthy Volunteers","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Immune Globulin Subcutaneous (Human)","20% Solution with Recombinant Human Hyaluronidase (rHuPH20)","Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (rHuPH20)","Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (rHuPH20).","Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase."],"phase":"phase_3","status":"active","brandName":"TAK-881","genericName":"TAK-881","companyName":"Takeda","companyId":"takeda","modality":"Biologic","firstApprovalDate":"","aiSummary":"TAK-881 is a selective, potent, and orally bioavailable inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes, Chronic kidney disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}